Natural Products Insider is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
HomeBusiness ResourcesBusiness OperationsLabs/TestingChromaDex Announces Top Line Results of its Second Human Clinical Trial

ChromaDex Announces Top Line Results of its Second Human Clinical Trial

<p>ChromaDex Corp. (NASDAQ:CDXC announced today that the initial results of its second human clinical study of NIAGEN<sup>&reg;</sup> nicotinamide riboside chloride (NR) have confirmed NR significantly and sustainably raises the co-enzyme nicotinamide adenine dinucleotide (NAD+) in 140 healthy human volunteers over 8-weeks.</p>
TAGS: Healthy Living Ingredients Business Resources
Hide comments
account-default-image
user not logged in

More information about text formats

Comments

  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Publish
Related
Creatine Whey and BCAAs
Protein shenanigans: Spiking, shortcutting quality and source mixing
May 10, 2022
Greed in the supplement market
Rumblings, musings on supply chain woes, greed in dietary supplements
May 10, 2022
Tammy Blakemore Melony Fuller.jpg
Women’s History Month: Tammy Blakemore—trailblazing educator, force for good
Mar 17, 2022
Atlantia Trials WP 222 copy 3.png
Paid Content
A crossover study of probiotics effects on mood, sleep and bowel symptoms in adults – white paper
Feb 28, 2022